Actinium Pharmaceuticals, Inc. (ATNM)의 가격은 얼마입니까?

Actinium Pharmaceuticals, Inc. (ATNM)의 가격은 $1.10입니다.

Actinium Pharmaceuticals, Inc. (ATNM)의 시가 총액은 무엇입니까?

Actinium Pharmaceuticals, Inc. (ATNM)의 시가 총액은 $34.64M입니다.

Actinium Pharmaceuticals, Inc. (ATNM) 가격 이력

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing and commercializing treatments, primarily focusing on those for bone marrow transplant (BMT) or other cellular and adoptive cell therapies. Its leading drug candidate, I-131 apamistamab (known as Iomab-B), is currently in a crucial Phase III clinical trial for its role in conditioning elderly patients with relapsed or refractory acute myeloid leukemia prior to BMT. Additionally, Iomab-B is being evaluated in a Phase I study for its use with CD19-targeted CAR T-cell therapy, a partnership with Memorial Sloan Kettering Cancer Center. The company's pipeline also includes several clinical and preclinical development programs that harness various isotopes such as Actinium-225, Iodine-131, and Lutetium-177. These programs are designed to target a range of validated cancer markers, including CD45, CD33, CD38, CD47, HER2, and HER3. Their applications span targeted conditioning regimens for cell and gene therapies, such as bone marrow transplantation, and as standalone or combination cancer therapeutics. Actinium has established strategic alliances, including a collaboration with Astellas Pharma, Inc. to create theranostics for solid tumor indications. Another partnership is with EpicentRx, Inc., concentrating on an innovative CD47 immunotherapy delivered via targeted radiotherapy. Furthermore, the company is working with AVEO Oncology on developing a HER3-targeting Antibody-Radio Conjugate (ARC) for solid tumors. Incorporated in 2000, Actinium Pharmaceuticals, Inc. is headquartered in New York, New York.

연도	성과
2026 (TTM)	-14.63%
2025	18.85%
2024	-75.34%
2023	-52.01%
2022	60.20%
2021	-37.95%
2020	57.83%
2019	-47.21%
2018	-36.61%
2017	-30.98%
2016	-57.41%
2015	-60.88%
2014	-10.34%
2013	335.37%
2012	0.00%

연도

성과

2026 (TTM)

-14.63%

2025

18.85%

2024

-75.34%

2023

-52.01%

2022

60.20%

2021

-37.95%

2020

57.83%

2019

-47.21%

2018

-36.61%

2017

-30.98%

2016

-57.41%

2015

-60.88%

2014

-10.34%

2013

335.37%

2012

0.00%

회사	주가	변동률 1년%	국가
Vertex Pharmaceuticals Incorporated VRTX.US	$552.07	39.99%	US
Moderna, Inc. MRNA.US	$168.77	527.63%	US
Argenx SE ARGX.US	$1.03K	56.22%	NL
CSL Limited CSL.AX	$120.74	-14.98%	AU
Lonza Group AG LONN.SW	$758.23	6.53%	CH

회사

주가

변동률 1년%

국가